Condition 1: Anxiety disorder. Condition 2: Depressive disorder. Anxiety disorder due to known physiological condition Mood disorder due to known physiological condition with major depressive-like episode
Conditions
Interventions
Intervention 1: First intervention group: The first group will receive 75 to 150 mg of oral pregabalin per day. Intervention 2: Second intervention group: Patients in this group will receive 100 to 60
Sponsors
Shahid Beheshti University of Medical Sciences
Eligibility
Sex/Gender
All
Age
18 Years to 65 Years
Inclusion criteria
Inclusion criteria: 18 to 65 years old. Suffering from depression or anxiety. Taking Sertraline (50-100mg) or Citalopram (20-40mg) or Escitalopram (10mg). Consent to enter the research. Be married.
Exclusion criteria
Exclusion criteria: Refusing to fill the questionnaire. Getting divorced or reaching menopause Taking medications other than those listed. Pregnancy or lactation. Having substance abuse during the study. Being allergic to Pregabalin or Gabapentin.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Sexual Dysfunctions. Timepoint: One Month. Method of measurement: The International Index of Erectile function Questionnaire; The Female Sexual Function Index Questionnaire.;Drowsiness. Timepoint: One Month. Method of measurement: Questionnaire.;Dizziness. Timepoint: One Month. Method of measurement: Questionnaire. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactDr. Maria Tavakoli Ardakani
Shahid Beheshti University of Medical Sciences
Outcome results
None listed